¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"clinical cooperative group"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • glucophore group
    ´Ü¸À´Ü
  • group
    1. ±º, ¹«¸®, Áý´Ü 2. ±â 3. Á· 4. ±×·ì
  • group antigen
    ¹«¸®Ç׿ø, ±ºÇ׿ø
  • group audiometry
    Áý´Üû·Â°Ë»ç
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢
  • group dynamics
    Áý´Ü¿ªÇÐ, Áý´Ü¿ªµ¿
  • group fascicular repair
    ½Å°æ¼¶À¯´Ù¹ß±ººÀÇÕ(¼ú)
  • group medicine
    Áý´ÜÁø·á, Çùµ¿Áø·á
  • group practice
    Áý´Ü°³¿ø, Áý´Ü°³¾÷
  • group psychotherapy
    Áý´ÜÁ¤½Å¿ä¹ý
  • group reference value
    Áý´ÜÂü°íÄ¡
  • group-specific
    ±ºÆ¯ÀÌ-
  • group-specific antigen
    ¹«¸®Æ¯ÀÌÇ׿ø, ±ºÆ¯ÀÌÇ׿ø
  • high risk group
    °íÀ§Ç豺
  • haptenic group
    ºÒ¿ÏÀüÇ׿ø±º, ÇÕÅÙ±º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • borderline group
    °æ°è±º
  • coliform group
    ´ëÀå±Õ±º
  • complementation group
    »óº¸¼ºÁý´Ü
  • complementophil group
    º¸Ã¼Ä£È­±â
  • control group
    ´ëÁ¶±º
  • determinant group
    °áÁ¤±º
  • diagnosis related group
    À¯»çÁø´Ü±ºÀÇ·áºñÁöºÒ¹ý
  • didactic group therapy
    ±³À°Áý´Ü¿ä¹ý
  • directive group therapy
    Áö½ÃÁý´Ü¿ä¹ý
  • group dynamics
    Áý´Ü¿ªÇÐ, Áý´Ü¿ªµ¿
  • end group
    ¸»´Ü±â
  • end group spine
    ±ê³¡°¡½Ã
  • enteric group
    âÀÚ±Õ±º
  • evocative group therapy
    Ç¥ÇöÁý´Ü¿ä¹ý
  • functional group
    ÀÛ¿ë±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • group file
    ±×·ì È­ÀÏ
  • group hearing aid
    Áý´Üº¸Ã»±â
  • group hospital
    º´¿øÁ¶ÇÕ(ËÓËô̡̰).
  • group incompatibility
    Ç÷¾×±ººÎÀûÇÕ(úìäûÏØ ÝÕîêùê).
  • group medicine
    Áý´Ü<Çùµ¿>Áø·á.
  • group of isogenous chondrocyte
    ¿¬°ñ¼¼Æ÷¹«¸®
  • group of muscles
    ±ÙÀ°¹«¸®, ±Ù__ÐÉÏØ).
  • group of muscles
    ±ÙÀ°¹«¸®, ±Ù±º(ÐÉÏØ).
  • group practice
    Áý´Ü°³¾÷(̤ËÀ˧ ).
  • group psychotherapy
    Áý´ÜÁ¤½ÅÄ¡·á(ó¢Ó¥ïñãêö½Öû)(¿ä¹ý)
  • group reaction
    Áý´Ü¹ÝÀÀ(̤ËÀËÑËô).
  • group reference value
    Áý´Ü±âÁØ<--ÂüÁ¶>Ä¡
  • group specific C carbohydrate
    ±ºÆ¯ÀÌ C´Ù´çü.
  • group test
    Áý´Ü½ÃÇè(ÊÙËàÌ´).
  • group-specific
    ±ºÆ¯ÀÌÀÇ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • clinical trial
    ÀÓ»ó½ÃÇè
  • clinical unit
    ÀÓ»ó´ÜÀ§(¡­Ó¤êÈ).
  • clinical use
    ÀÓ»óÀû(ÀÎ) ÀÌ¿ë
  • clinical virology
    ÀÓ»ó¹ÙÀÌ·¯½ºÇÐ
  • clinical ward
    ÀÓ»óº´µ¿(¡­Ü»ÔÖ).
  • clinical-pathological correlation
    ÀÓ»ó-º´¸®ÇÐÀû »óÈ£°ü°è(ìúßÉ-Ü»×âùÊîÜ ßÓû»Î¼Ìõ)
  • controlled clinical study
    (Ãß°èÇÐÀû) °ü¸®È­(Ì§Ë­Ì°ËøË´ËöÌ´)(ÀÓ»ó)½ÃÇè( ËöË×ËàÌ´).
  • mycology, clinical
    ÀÓ»óÁø±ÕÇÐ
  • randomized clinical trial
    ¹«ÀÛÀ§ÀÓ»ó½ÇÇè
  • structured clinical interview
    ±¸Á¶È­µÈ ÀÓ»ó¸éÁ¢(ìúßÉØüïÈ).
  • validity of clinical study
  • amino group
    ¾Æ¹Ì³ë±â(¡­Ðñ).
  • analytic group psychotherapy
    ºÐ¼®Àû Áý´Ü Á¤½ÅÄ¡·á
  • anterior sinus group
    ÀüºÎºñµ¿±º
  • atomic group
    ¿øÀÚ´Ü.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • guanidino group
    ±¸¾Æ´Ïµð³ë±â(Ðñ)
  • guanido group
    ±¸¾Æ´Ïµµ±â(Ðñ)
  • haptenic group
    ÇÕÅÙ±â(Ðñ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • hydroxymethyl group
    ÇÏÀ̵å·Ï½Ã¸ÞÆ¿±â(Ðñ)
  • hypsochromic group
    û»öÀ̵¿±â(ôìßäì¹ÔÑÐñ)
  • imidazole group
    À̴̹ÙÁ¹±â(Ðñ)
  • imino group
    À̹̳ë±â(Ðñ)
  • Inv group
    Inv ±º(ÏØ)
  • ketone group
    ÄÉÅæ±â(Ðñ)
  • labile methyl group
    ºÒ¾ÈÁ¤(ÝÕäÌïÒ)¸ÞÆ¿±â(Ðñ)
  • labile phosphate group
    ºÒ¾ÈÁ¤Àλê±â(ÝÕäÌïÒ×ò߫Ѩ)
  • leaving group
    ÀÌÅ»±â(×î÷­Ðñ)
  • linkage group
    ¿¬°ü±º(Ö¤Î¼ÏØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CHSS cooperative health statistics system
CONSENSUS Cooperative North Scandinavian Enalapril Survival Study
COOP charts for primary care practices; cooperative
CSP carotid sinus pressure; cavum septi pellucidi; cell surface protein; cerebrospinal protein; Chartere...
HIPC health insurance purchasing collective; health insurance purchasing cooperative
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
Group I group
group II group I
Group III group
ASCO American Society of Clinical Oncology
CAI Clinical Activity Index
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Rh blood group
    Rh Ç÷¾×Çü, ¾Æ¸£ ¿¡ÀÌÄ¡½Ä Ç÷¾×Çü
    1940³â ¹Ì±¹ÀÇ K. ¶õÆ®½´Å¸ÀÌ³Ê µî¿¡ ÀÇÇÏ¿© ¹ß°ßµÈ ÀÓ»óÀûÀ¸·Î ¾ÆÁÖ Áß¿äÇÑ Ç÷¾×Çü. Rh¶ó´Â °ÍÀº, óÀ½¿¡ À̰ÍÀ» °ËÃâÇϴµ¥ ÇÊ¿äÇÑ Ç×Ç÷ûÀ» ¾ò±â À§ÇÏ¿© »ç¿ëÇÑ ¸é¿ª µ¿¹°ÀÎ ºÓÀºÅпø¼þÀÌ
  • S-blood group
    ¿¡½º½Ä Ç÷¾×Çü
    ABO½Ä Ç÷¾×Çü°ú °ü°è ÀÖ´Â Ç÷¾×Çü. Ç÷¾×ÀÇ ºÐºñÇü, ºñºÐºñÇüÀÇ ºÐ·ù¶ó°í Çϸç, 1932³â µ¶ÀÏÀÇ F. ½ÃÇÁ°¡ ¹ß°ßÇÏ¿´´Ù. ABO½Ä Ç÷¾×Çü¿¡ ¼ÓÇÏ´Â Ç׿ø ¹°Áú
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
clinical spectroscopy Spectroscopic examination of specimens of living tissue, including fluids removed therefrom.
Synonym: clinical spectroscopy.
Origin: bio-+ L. Spectrum, image, + G. Skopeo, to examine
(05 Mar 2000)
clinical studies <pharmacology> Human studies that are designed to measure the safety, efficacy, and appropriate dosage of a new drug or biological. Clinical studies routinely involve the use of a placebo group that is given an inactive substance that looks like the test product.
(14 Nov 1997)
clinical syndrome <syndrome> A clinical syndrome represents a typical constellation of physical (and laboratory) findings that may be seen as part of a primary disease process.
A good example is shock, a clinical syndrome seen with many primary disease processes.
(13 Nov 1997)
clinical thermometer A small, self-registering thermometer, consisting of a simple scaled glass tube containing mercury, used for taking the temperature of the body.
(05 Mar 2000)
clinical trial <pharmacology> Research study conducted with patients, usually to evaluate a new treatment or drug. Each trial is designed to answer scientific questions and to find better ways to treat individuals with a specific disease.
(12 May 1997)
clinical trial, phase I A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase II A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase III A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product.
(12 Dec 1998)
clinical trials Medical research studies conducted with volunteers. Each study is designed to answer scientific questions and to find better ways to prevent, detect, or treat cancer.
(12 Dec 1998)
clinical trials, phase I Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase II Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
controlled clinical trial A clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterised as a randomised controlled trial. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes are simply designated as controlled clinical trials.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • habitat group
    »ýÅ·ù(¼­½Ä ȯ°æÀ» °°ÀÌ ÇÏ´Â µ¿½Ä¹°);(¹Ú¹°°ü¿¡ Àü½ÃµÈ)»ý¹° ȯ°æ ¸ðÇü
  • income group
    »çȸ ¼ÒµæÃþ(µ¿ÀÏ ¼Òµæ¼¼¾×Áý´Ü)
  • informal group
    (»çȸ)ºñ°ø½ÄÀû Áý´Ü(°üû°øÀåµî¿¡¼­ÀÇ)
  • interested group
    (»çȸ)ÀÌÀͰøµ¿Ã¼;°øÅëÀÌÇØ´Üü(±¹°¡ Á¤´çŬ·´µî)
  • minority group
    ¼Ò¼ö¹ÎÁ·(Çѳª¶óÀÇ)
  • peer group
    µ¿·á Áý´Ü;µ¿¹è Áý´Ü
  • pressure group
    ¾Ð·Â ´Üü
  • primary group
    Á¦ ÀÏÂ÷ Áý´Ü(°¡Á¤,Ä£±¸ µî)
  • rape group
    ÅäÀÇ(Åä·Ð)±×·ì
  • reference group
    ÁذŠÁý´Ü(°³ÀÎÀÌ ÀÚ±â ŵµ.ÆÇ´ÜÀÇ ±âÁØÀ¸·Î ¿©±â´Â ƯÁ¤ Áý´Ü)
  • splinter group
    ºÐÆÄ;¼Ò¼öÆÄ
  • tail group
    TAIL UNIT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á